Cargando…
Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF‐CC) in Subjects With Severe Hemophilia A
An open‐label, single‐dose, randomized, two‐period, crossover study comparing the pharmacokinetics of factor VIII activity in plasma (FVIII:C) after administration of an albumin‐free presentation of moroctocog alfa (test) and moroctocog alfa manufactured using the previous technique (reference) was...
Autores principales: | Korth‐Bradley, Joan, Rupon, Jeremy, Plotka, Anna, Charnigo, Robert, Rendo, Pablo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944578/ https://www.ncbi.nlm.nih.gov/pubmed/29575770 http://dx.doi.org/10.1111/cts.12544 |
Ejemplares similares
-
Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies
por: Yang, Renchi, et al.
Publicado: (2020) -
Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India
por: Choraria, Nirmalkumar, et al.
Publicado: (2022) -
Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa
por: Rendo, Pablo, et al.
Publicado: (2018) -
Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India
por: Choraria, Nirmalkumar, et al.
Publicado: (2022) -
Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
por: Lissitchkov, Toshko, et al.
Publicado: (2023)